The global hereditary cancer testing market is experiencing strong expansion as healthcare systems increasingly adopt genetic diagnostics for early detection and preventive oncology. Valued at US$ 5.05 billion in 2021, the market is projected to reach US$ 14.59 billion by 2031, reflecting robust growth driven by rising cancer prevalence and advancements in molecular technologies. A detailed Hereditary Cancer Testing Market Segmentation Analysis shows that the industry is primarily segmented by test type, technology, application, and end user, with significant demand growth across multi-gene panel testing, next-generation sequencing (NGS), and oncology-focused clinical applications.

By test type, multi-gene panel testing is gaining strong traction due to its ability to analyze multiple cancer-related genes simultaneously, offering comprehensive risk assessment in a single test. Single-gene testing still holds relevance in specific hereditary conditions but is gradually being replaced by more advanced panel-based approaches. This shift is enhancing diagnostic efficiency and improving clinical decision-making in oncology care.

Download Sample PDF: https://www.theinsightpartners.com/sample/TIPRE00006578

Based on technology, next-generation sequencing (NGS) dominates the hereditary cancer testing market due to its high accuracy, scalability, and cost-effectiveness. NGS allows for rapid sequencing of large genetic datasets, making it highly suitable for detecting complex hereditary mutations. Polymerase chain reaction (PCR) and microarray-based technologies continue to support niche applications, particularly in targeted genetic analysis.

In terms of application, breast cancer testing holds a significant share of the market due to the high prevalence of BRCA1 and BRCA2 mutations. Ovarian, colorectal, prostate, and other hereditary cancers also represent important application areas, driven by increasing awareness of genetic risk factors and expanding screening programs. The rising focus on early detection and preventive healthcare is further boosting adoption across all cancer types.

By end user, hospitals and diagnostic laboratories account for the largest share of the market due to the availability of advanced testing infrastructure and trained professionals. Academic and research institutions also play a key role in driving innovation and expanding the clinical understanding of hereditary cancer genetics. Additionally, increasing adoption of genetic testing in specialty clinics is contributing to market growth.

Geographically, North America dominates the hereditary cancer testing market owing to well-established healthcare infrastructure, high awareness levels, and strong reimbursement frameworks. Europe follows closely, supported by government-led cancer screening initiatives. Meanwhile, Asia Pacific is expected to witness the fastest growth due to improving healthcare access, rising cancer incidence, and increasing investments in genomic medicine.

Key players in the hereditary cancer testing market include Illumina, Inc., Thermo Fisher Scientific Inc., Myriad Genetics, Inc., F. Hoffmann-La Roche Ltd, QIAGEN N.V., Agilent Technologies, Inc., Guardant Health, Inc., Invitae Corporation, BGI Genomics Co., Ltd., and Bio-Rad Laboratories, Inc. These companies are focusing on strategic collaborations, technological innovations, and expansion of test portfolios to strengthen their competitive positioning.

Overall, the hereditary cancer testing market is expected to grow significantly through 2031, driven by advancements in genomic technologies, increasing adoption of precision medicine, and rising global emphasis on early cancer detection and risk assessment.

About Us

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us

Ankit Mathur | The Insight Partners
E-mail: ankit.mathur@theinsightpartners.com
Phone: +1-646-491-9876

Also Available in : Korean | German | Japanese | French | Chinese | Italian | Spanish